纳米药物在子宫内膜异位症治疗中的应用进展

doi:10.12280/gjfckx.20251123

摘要/Abstract

摘要：

子宫内膜异位症（endometriosis，EMs）是一种常见的妇科良性疾病，目前主要治疗方法包括药物治疗和手术治疗，但均存在一定的局限性。EMs手术后仍需面临药物的长期管理以预防复发。因此，探寻新型有效且可耐受的药物治疗方式尤其重要。近年借助纳米技术传导药物的治疗已成为疾病治疗的新方式，纳米药物具有靶向性、改善药代动力学、延长循环时间、增加难溶性药物的生物利用度及多模式整合等优势，已成功应用于多种肿瘤疾病的治疗。EMs同样具有类似肿瘤细胞的生物学行为，可将纳米药物应用于肿瘤治疗方面的策略应用于EMs治疗。目前纳米药物在EMs治疗中的应用包括抗氧化疗法和抗炎疗法、疼痛治疗、免疫治疗、光热疗法、基因治疗及多模式诊疗。综述纳米药物在EMs治疗应用中的相关研究，为临床医生治疗EMs提供新的方向。

关键词: 纳米粒子, 子宫内膜异位症, 药物释放系统, 药物疗法, 治疗

Abstract:

Endometriosis (EMs) is a common benign gynecological disease. Currently, the main treatment methods include drug therapy and surgical treatment, but both have certain limitations. Even after EMs surgery, long-term drug management is still required to prevent recurrence. Therefore, it is particularly important to explore new, effective, and well-tolerated drug treatment modalities. In recent years, drug delivery using nanotechnology has become a new approach for disease treatment. Nanomedicine has advantages such as targeting, improving pharmacokinetics, prolonging circulation time, increasing the bioavailability of poorly soluble drugs, and multi-mode integration, and has been successfully applied in the treatment of various tumor diseases. EMs also exhibits biological behaviors similar to those of tumor cells, so the strategies of applying nanomedicine in tumor treatment can be used in the treatment of EMs. Currently, the applications of nanomedicine in the treatment of EMs include antioxidant and anti-inflammatory therapies, pain treatment, immunotherapy, photothermal therapy, gene therapy, and multi-mode diagnosis and treatment. This review summarizes the relevant research on the application of nanomedicine in the treatment of EMs, providing new directions for clinicians in treating EMs.

Key words: Nanoparticles, Endometriosis, Drug delivery systems, Drug therapy, Therapy

吴佩阳, 卢珺, 蓝喜, 梁炎春. 纳米药物在子宫内膜异位症治疗中的应用进展[J]. 国际妇产科学杂志, 2026, 53(1): 60-64.

WU Pei-yang, LU Jun, LAN Xi, LIANG Yan-chun. Advances in the Application of Nanomedicine in the Treatment of Endometriosis[J]. Journal of International Obstetrics and Gynecology, 2026, 53(1): 60-64.

参考文献 35

[1]	Horne AW, Missmer SA. Pathophysiology, diagnosis, and management of endometriosis[J]. BMJ, 2022, 379:e070750. doi: 10.1136/bmj-2022-070750.
[2]	Rossi HR, Uimari O, Terho A, et al. Increased overall morbidity in women with endometriosis: a population-based follow-up study until age 50[J]. Fertil Steril, 2023, 119(1):89-98. doi: 10.1016/j.fertnstert.2022.09.361.
[3]	中华预防医学会生殖健康分会, 中国医师协会妇产科医师分会子宫内膜异位症学组, 戴毅. 子宫内膜异位症疼痛管理指南(2024年实践版)[J]. 中国实用妇科与产科杂志, 2024, 40(1):50-61. doi: 10.19538/j.fk2024010114.
[4]	Becker CM, Bokor A, Heikinheimo O, et al. ESHRE guideline: endometriosis[J]. Hum Reprod Open, 2022, 2022(2):hoac009. doi: 10.1093/hropen/hoac009.
[5]	Ngernprom P, Klangsin S, Suwanrath C, et al. Risk factors for recurrent endometriosis after conservative surgery in a quaternary care center in southern Thailand[J]. PLoS One, 2023, 18(8):e0289832. doi: 10.1371/journal.pone.0289832.
[6]	Adamo FM, De Falco F, Dorillo E, et al. Nanotechnology Advances in the Detection and Treatment of Lymphoid Malignancies[J]. Int J Mol Sci, 2024, 25(17):9253. doi: 10.3390/ijms25179253.
[7]	Xu J, Song M, Fang Z, et al. Applications and challenges of ultra-small particle size nanoparticles in tumor therapy[J]. J Control Release, 2023, 353:699-712. doi: 10.1016/j.jconrel.2022.12.028.
[8]	Imperiale L, Nisolle M, Noël JC, et al. Diagnosis and Treatment. Three Types of Endometriosis: Pathogenesis, State of the Art[J]. J Clin Med, 2023, 12(3):994. doi: 10.3390/jcm12030994.
[9]	Powell SG, Sharma P, Masterson S, et al. Vascularisation in Deep Endometriosis: A Systematic Review with Narrative Outcomes[J]. Cells, 2023, 12(9):1318. doi: 10.3390/cells12091318.
[10]	Maeda H. Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting[J]. Proc Jpn Acad Ser B Phys Biol Sci, 2012, 88(3):53-71. doi: 10.2183/pjab.88.53.
[11]	Talukdar S, Singh SK, Mishra MK, et al. Emerging Trends in Nanotechnology for Endometriosis: Diagnosis to Therapy[J]. Nanomaterials(Basel), 2024, 14(11):976. doi: 10.3390/nano14110976.
[12]	Islam R, Maeda H, Fang J. Factors affecting the dynamics and heterogeneity of the EPR effect: pathophysiological and pathoanatomic features, drug formulations and physicochemical factors[J]. Expert Opin Drug Deliv, 2022, 19(2):199-212. doi: 10.1080/17425247.2021.1874916.
[13]	Ma J, Liao Z, Li J, et al. A cRGD-modified liposome for targeted delivery of artesunate to inhibit angiogenesis in endometriosis[J]. Biomater Sci, 2025, 13(4):1045-1058. doi: 10.1039/d4bm01506a.
[14]	Volpini C, Bloise N, Casali C, et al. AntiCD44 antibody-conjugated gold nanoparticles for targeted photothermal therapy of endometriotic cells[J]. Biomater Sci, 2025, 13(18):5164-5183. doi: 10.1039/d5bm00701a.
[15]	Wu N, Han Z, Lv W, et al. Reprogramming peritoneal macrophages with outer membrane vesicle-coated PLGA nanoparticles for endometriosis prevention[J]. Biomaterials, 2025, 319:123198. doi: 10.1016/j.biomaterials.2025.123198.
[16]	Liu H, Dai X, Li N, et al. Injectable Magnetic Hydrogel Incorporated with Anti-Inflammatory Peptide for Efficient Magnetothermal Treatment of Endometriosis[J]. Adv Sci(Weinh), 2024, 11(44):e2409778. doi: 10.1002/advs.202409778.
[17]	Tang Z, Zhang X, Meng S, et al. Cell Membrane Camouflaged and ROS Responsive Nanosomes for Targeted Endometriosis Therapy Via Reversing Inflammatory, Low-Autophagy, and Immunotolerant Microenvironment[J]. Chem Eng J, 2024, 493:152697. doi: 10.1016/j.cej..024.152697.
[18]	Liu X, Yan S, Wu H, et al. Interventional Hydrogel Microsphere Controlled‐Releasing Curcumin for Photothermal Therapy Against Endometriosis[J]. Adv Funct Mater, 2024, 34(26):2315907. doi: 10.1002/adfm.202315907.
[19]	Zhong Q, Yang S, Li X, et al. A Multifunctional Molecular Probe for Multimodal Imaging-Guided Potent Photothermal/Photodynamic Therapy of Endometriosis[J]. Adv Sci(Weinh), 2025, 12(43):e11126. doi: 10.1002/advs.202511126.
[20]	Slayden O, Luo F, Park Y, et al. Targeted nanoparticles for imaging and therapy of endometriosis[J]. Biol Reprod, 2024, 110(6):1191-1200. doi: 10.1093/biolre/ioae073. pmid: 38738758
[21]	Singh AK, Chakravarty B, Chaudhury K. Nanoparticle-Assisted Combinatorial Therapy for Effective Treatment of Endometriosis[J]. J Biomed Nanotechnol, 2015, 11(5):789-804. doi: 10.1166/jbn.2015.2020. pmid: 26349392
[22]	Egorova A, Maretina M, Krylova I, et al. Polycondensed Peptide-Based Polymers for Targeted Delivery of Anti-Angiogenic siRNA to Treat Endometriosis[J]. Int J Mol Sci, 2023, 25(1):13. doi: 10.3390/ijms25010013.
[23]	Wu T, Guo Y. ATP/P2X4 Regulates Inflammation and Oxidative Stress in Endometriosis Through NLRP3 Inflammasome-Dependent Mechanisms[J]. Am J Reprod Immunol, 2025, 94(2):e70132. doi: 10.1111/aji.70132.
[24]	Dymanowska-Dyjak I, Frankowska K, Abramiuk M, et al. Oxidative Imbalance in Endometriosis-Related Infertility-The Therapeutic Role of Antioxidants[J]. Int J Mol Sci, 2024, 25(12):6298. doi: 10.3390/ijms25126298.
[25]	Irimia T, Puşcaşiu L, Mitranovici MI, et al. Oxidative-Stress Related Gene Polymorphism in Endometriosis-Associated Infertility[J]. Medicina(Kaunas), 2022, 58(8):1105. doi: 10.3390/medicina58081105.
[26]	Chaudhury K, Babu KN, Singh AK, et al. Mitigation of endometriosis using regenerative cerium oxide nanoparticles[J]. Nanomedicine, 2013, 9(3):439-448. doi: 10.1016/j.nano.2012.08.001. pmid: 22960424
[27]	Boroumand S, Hosseini S, Pashandi Z, et al. Curcumin-loaded nanofibers for targeting endometriosis in the peritoneum of a mouse model[J]. J Mater Sci Mater Med, 2019, 31(1):8. doi: 10.1007/s10856-019-6337-4.
[28]	Ding S, Yu Q, Wang J, et al. Activation of ATF3/AP-1 signaling pathway is required for P2X3-induced endometriosis pain[J]. Hum Reprod, 2020, 35(5):1130-1144. doi: 10.1093/humrep/deaa061.
[29]	Yuan M, Ding S, Meng T, et al. Effect of A-317491 delivered by glycolipid-like polymer micelles on endometriosis pain[J]. Int J Nanomedicine, 2017, 12:8171-8183. doi: 10.2147/IJN.S146569.
[30]	Liu Q, Ma P, Liu L, et al. Evaluation of PLGA containing anti-CTLA4 inhibited endometriosis progression by regulating CD4+CD25+Treg cells in peritoneal fluid of mouse endometriosis model[J]. Eur J Pharm Sci, 2017, 96:542-550. doi: 10.1016/j.ejps.2016.10.031. pmid: 27989857
[31]	Moses AS, Taratula OR, Lee H, et al. Nanoparticle-Based Platform for Activatable Fluorescence Imaging and Photothermal Ablation of Endometriosis[J]. Small, 2020, 16(18):e1906936. doi: 10.1002/smll.201906936.
[32]	Guo X, Li W, Zhou J, et al. Specific Photothermal Ablation Therapy of Endometriosis by Targeting Delivery of Gold Nanospheres[J]. Small,2017 Apr; 13(15). doi: 10.1002/smll.201603270.
[33]	Liang Z, Chen Y, Zhao Y, et al. miR-200c suppresses endometriosis by targeting MALAT1 in vitro and in vivo[J]. Stem Cell Res Ther, 2017, 8(1):251. doi: 10.1186/s13287-017-0706-z. pmid: 29116025
[34]	Chaichian S, Mehdizadeh Kashi A, Tehermanesh K, et al. Effect of PLGA Nanoparticle-Mediated Delivery of miRNA 503 on The Apoptosis of Ovarian Endometriosis Cells[J]. Cell J, 2022, 24(11):697-704. doi: 10.22074/cellj.2022.557554.1069. pmid: 36377220
[35]	Zhao M, Zhang M, Yu Q, et al. Hyaluronic Acid-Modified Nanoplatforms as a Vector for Targeted Delivery of Autophagy-Related Gene to the Endometriotic Lesions in Mice[J]. Front Bioeng Biotechnol, 2022, 10:918368. doi: 10.3389/fbioe.2022.918368.